Oncimmune Holdings PLC | Mutual Funds
Mutual Funds that own Oncimmune Holdings PLC
CF Ruffer Investment Funds - Total Return Fund
3,334,239
5.41%
0
0.18%
04/30/2018
Fidelity Funds SICAV - European Smaller Companies Fund
1,418,477
2.29%
-3,503
0.16%
03/31/2018
Amati VCT 2 Plc
398,545
0.65%
398,545
0.67%
01/31/2018
Fidelity Funds SICAV - International Fund
71,941
0.12%
1,634
0.01%
03/31/2018
Fidelity Funds SICAV - Sélection Internationale
17,452
0.03%
307
0.01%
03/31/2018
Fidelity Funds SICAV - Patrimoine
12,958
0.02%
53
0.01%
05/31/2018
Fidelity Funds SICAV - Target 2040 (EUR) Fund
9,214
0.02%
389
0.01%
03/31/2018
Fidelity Funds SICAV - Target 2030 (EUR) Fund
8,370
0.01%
294
0.01%
03/31/2018
Fidelity Funds SICAV - Target 2025 (EUR) Fund
6,103
0.01%
178
0.01%
03/31/2018
Fidelity Funds SICAV - Target 2035 (EUR) Fund
5,883
0.01%
251
0.01%
03/31/2018
| Address |
Clinical Sciences Building
Nottinghamshire Nottingham NG5 1PB
United Kingdom
|
|
Employees
|
- |
| Website |
http://www.oncimmune.com |
| Updated |
07/08/2019 |
| Oncimmune Holdings Plc is an early cancer detection company that engages in the development and commercialization of its proprietary EarlyCDT platform technology. It has pioneer the development of tests based on the presence in the blood of autoantibody against specific tumor associated antigens that have the potential to detect cancer up to four years earlier than other methods of cancer detection, such as a chest X-ray, Spiral Computed Tomography or emerging technologies that do not benefit from the amplification of signal that occurs with the immune system, and can be applied to a very wide range of solid tumor types. The company was founded on October 9, 2015 and is headquartered in Nottinghamshire, the United Kingdom. |
